Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.10.0.1
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Net sales $ 174,510 $ 154,153 $ 337,480 $ 298,766
Operating income 33,603 24,148 59,364 50,179
Costs recognized on sale of acquired inventory     (1,869) (582)
Amortization of acquisition related intangible assets     (29,354)  
Corporate general, selling, and administrative expenses (63,603) (63,775) (130,655) (122,064)
Operating Segments [Member]        
Operating income 57,897 56,106 115,047 109,594
Operating Segments [Member] | Protein Sciences [Member]        
Net sales 135,462 117,142 261,852 225,255
Operating income 58,951 50,218 113,565 96,427
Operating Segments [Member] | Diagnostics and Genomics [Member]        
Net sales 39,263 37,086 76,010 73,675
Operating income (1,054) 5,888 1,482 13,167
Intersegment Eliminations [Member]        
Net sales (215) (75) (382) (164)
Segment Reconciling Items [Member]        
Costs recognized on sale of acquired inventory (935) (264) (1,869) (582)
Amortization of acquisition related intangible assets (15,002) (11,296) (29,278) (22,675)
Acquisition related expenses (348) (13,150) (2,973) (22,683)
Stock based compensation (6,861) (5,044) (18,426) (8,839)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative expenses $ (1,148) $ (2,204) $ (3,137) $ (4,636)